Digital Library
Close Browse articles from a journal
 
Search for with title:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             81 results found
no title author magazine year volume issue page(s) type
1 Accelerated Approval Paths: What they do Mean and What they Should Not Mean? Calvo, G.
 2016
 38 10S p. e1-
1 p.
 article
2 Adherence to Antiretroviral Therapy: Experience of Pharmaceutical Services of Maputo Central Hospital Cumaquela, F.
 2016
 38 10S p. e26-
1 p.
 article
3 Adherence To Pharmacological Treatment Of Chronic Non-Malignant Pain In Individuals Aged 65 and Older Markotic, F.
 2016
 38 10S p. e11-
1 p.
 article
4 Allele Frequency Distribution of CYP2C19 Genotypes Associated with Clopidogrel Resistance in Russian Population Barysheva, V.
 2016
 38 10S p. e25-e26
nvt p.
 article
5 A Model For Managed Introduction Of New Medicines In Sweden Böttiger, Y.
 2016
 38 10S p. e13-e14
nvt p.
 article
6 Antibiotic Use In Hospital Setting: Have Pharmacists An Active Role? Roque, F.
 2016
 38 10S p. e29-
1 p.
 article
7 Anticoagulation For The Prevention of Stroke In Non-Vavular Af In General Practice: Room For Improvement Ioannou, A.
 2016
 38 10S p. e29-e30
nvt p.
 article
8 Application of Physiologically Based Pharmacokinetic Modeling In Predicting Drug-Drug Interactions For Sarpogrelate Hydrochloride In Humans Min, J.S.
 2016
 38 10S p. e32-
1 p.
 article
9 Are we Scared of Clinical Trials if not Sufficiently Informed and Educated? Burnazovic-Ristic, L.
 2016
 38 10S p. e4-e5
nvt p.
 article
10 Attitudes to Performing Clinical Trials Potocnjak, I.
 2016
 38 10S p. e5-
1 p.
 article
11 Availability and Affordability of Cardiovascular Medicines In Armenia Sevikyan, A.L.
 2016
 38 10S p. e27-
1 p.
 article
12 Availability of Information on use of Medicines in Children in Reference Books Melikyan, M.V.
 2016
 38 10S p. e21-
1 p.
 article
13 Can Vascular Calcification be Associated with Warfarin Treatment? Siltari, A.
 2016
 38 10S p. e25-
1 p.
 article
14 Can You Blindly Trust Decisions Made By Stringent Drug Regulatory Agencies? Ahmad, S.R.
 2016
 38 10S p. e30-
1 p.
 article
15 Clinical Drug-Drug Interaction Studies: Methods, Pitfalls, and Interpretation Backman, J.T.
 2016
 38 10S p. e1-e2
nvt p.
 article
16 Clinically Guided Warfarin Dose Versus Genotyping In Early Achievement Of Stable Anticoagulant Effect Of Warfarin Makar-Ausperger, K.
 2016
 38 10S p. e10-
1 p.
 article
17 Clinical Pharmacology As A Key Principle Of Precision Medicine In Korea Shin, J.G.
 2016
 38 10S p. e7-
1 p.
 article
18 Clinical Safety and Efficacy Issues Ariding in Relation to Alternative Formulations of nti Drugs Relevant to National Policy Development and Reimbursement Decisions – Focus on Calcineurin Inhibitors (cni) Undre, N.
 2016
 38 10S p. e15-
1 p.
 article
19 Comparison Of Sorafenib Cost-Effectiveness And Budget Impact When Used For Advanced Hepatocellular Carcinoma In Two Neighbouring Balkan Countries Jankovic, S.M.
 2016
 38 10S p. e16-e17
nvt p.
 article
20 Cost Utility Analysis Of Selected Medical Equipment And Procedures In Croatia Korolija Marinic, D.
 2016
 38 10S p. e15-
1 p.
 article
21 Current Challenges and Hurdles in New Drug Development Vukicevic, S.
 2016
 38 10S p. e3-
1 p.
 article
22 Current Situation And Future Directions For Health Technology Assessment In Europe Meyer, F.
 2016
 38 10S p. e14-e15
nvt p.
 article
23 Decentralized Decision Making On Drug Reimbursement In A Middle-Income Country: Case Of Bosnia And Herzegovina Mahmic-Kaknjo, M.
 2016
 38 10S p. e17-
1 p.
 article
24 Direct Medical Costs Of Treating Colorectal Cancer Patients With Different Chemotherapy Protocols Regarding Stage And Outcome Of The Disease Kovacevic, A.
 2016
 38 10S p. e17-
1 p.
 article
25 Drug-Drug Interaction of Paroxetine and Atomoxetine in Different CYP2D6 Genotypes Kim, Y.H.
 2016
 38 10S p. e23-
1 p.
 article
26 Effectiveness Assessment When Pharmacokinetics Makes A Difference, Macrolides And Azalide Example Francetic, I.
 2016
 38 10S p. e8-e9
nvt p.
 article
27 Effect of Ondansetron On The Thermal Antinociceptive Effects of Procaine In The Rat Paw Hanedan, B.
 2016
 38 10S p. e31-e32
nvt p.
 article
28 Effects of ABCB1 Genetic Polymorphism on the Oral Absorption of Losartan Byeon, J.Y.
 2016
 38 10S p. e22-
1 p.
 article
29 Effects of Celastrol on Bv-2 Microglial Cells Exposed to in Vitro Hypoxia Rački, V.
 2016
 38 10S p. e21-
1 p.
 article
30 Effects of Genetic Polymorphism of Cyp2c19 on the Pharmacokinetics of Zolpidem Byeon, J.Y.
 2016
 38 10S p. e22-e23
nvt p.
 article
31 Efficacy of Antidepressants: Issues Related to Bias in Clinical Trials Spina, E.
 2016
 38 10S p. e2-
1 p.
 article
32 Evaluation of Drugs in the Pediatric Population Mimica Matanovic, S.
 2016
 38 10S p. e2-
1 p.
 article
33 Evaluation Of Medicines For Reimbursement By The National Social Insurance Institutions In Austria Griesbacher, T.
 2016
 38 10S p. e14-
1 p.
 article
34 Excellence in Clinical Research: Clinical Trial Design Simon, T.
 2016
 38 10S p. e19-
1 p.
 article
35 Experience from Development of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Dulaglutide for Treatment of Type 2 Diabetes Mellitus Milicevic, Z.
 2016
 38 10S p. e1-
1 p.
 article
36 Following Guidelines and Prescribing Biological Medicine In A Situation of Reduced Budget Zekić, T
 2016
 38 10S p. e27-
1 p.
 article
37 Food And Drug Interactions Bago, M.
 2016
 38 10S p. e10-
1 p.
 article
38 Frequency of Potentially Dangerous Drug Combination Prescription in Elderly Patients with Cardiovascular Diseases Bordovsky, S.
 2016
 38 10S p. e22-
1 p.
 article
39 Genetic and Non-Genetic Factors Affecting The Response To Clopidogrel Therapy Mugosa, S.
 2016
 38 10S p. e11-
1 p.
 article
40 Health Technology Assessment (Hta) In Croatia: National And International View Huic, M.
 2016
 38 10S p. e16-
1 p.
 article
41 How To Assess The Value Of The Drug? An Overview On Producing Economic Evidence In The R&D Process Kaló, Z.
 2016
 38 10S p. e14-
1 p.
 article
42 How to Promote Clinical Research in Cee? Spaventi, R.
 2016
 38 10S p. e3-
1 p.
 article
43 Implementation of Pharmacoeconomics to Support Pharmaceutical R&D Decisions Workshop Kaló, Z.
 2016
 38 10S p. e19-
1 p.
 article
44 Inconsistency in Preclinical and Clinical Trials Exploring The Role of Hormone Replacement Therapy in Alzheimer’s Disease Osmanovic-Barilar, J.
 2016
 38 10S p. e4-
1 p.
 article
45 Integrating Pharmacovigilance and Pharmacogenomics: Croatian Experience Bozina, N.
 2016
 38 10S p. e23-
1 p.
 article
46 Managing Increasing Expenses For Oncology Treatment In Lower Income Countries In Europe Bolanča, Slobodanka
 2016
 38 10S p. e15-e16
nvt p.
 article
47 Medicinal Product Regulation: Portugal’s Framework Herdeiro, M.T.
 2016
 38 10S p. e3-e4
nvt p.
 article
48 Medicines for Pain and Palliative Care in Armenia Kazaryan, I.A.
 2016
 38 10S p. e21-e22
nvt p.
 article
49 Neuroprotective And Memory-Enhancing Effects of The Water Extract From Pericarp of Mangosteen Fruit Cho, J.
 2016
 38 10S p. e31-
1 p.
 article
50 New drugs for bad bugs: what’s new and what’s in the pipeline? Turk, V. Erdeljic
 2016
 38 10S p. e9-
1 p.
 article
51 New Methods and Designs of Clinical Trials Pontes, C.
 2016
 38 10S p. e2-e3
nvt p.
 article
52 Osteogrow Development: Bmp6 Bone Device For Enhancing Bone Healing Grgurevic, L.
 2016
 38 10S p. e9-e10
nvt p.
 article
53 Outlook For Biosimilar Molecules Entering Croatian Pharmaceutical Market In The Period From 2016 To 2020 Likic, R.
 2016
 38 10S p. e16-
1 p.
 article
54 Outpatient Use of Antidepressants And The Incidence of Suicide In Montenegro 2000-2015: Are We Going In Optimistic Direction? Duborija-Kovacevic, N.
 2016
 38 10S p. e28-e29
nvt p.
 article
55 Patient with Multiple Drugs Intolerance: Oral Drug Provocation Test Havidic, A.
 2016
 38 10S p. e23-e24
nvt p.
 article
56 Personalised Medicine Approaches For Identifying Effective Therapies Singer, D.R.J.
 2016
 38 10S p. e7-
1 p.
 article
57 Pharmaceutical Pricing: How Much for The Risk Of Non-Cure? Mance, D.
 2016
 38 10S p. e17-e18
nvt p.
 article
58 Pharmacoeconomic Analysis of Antithrombotic Treatment In Coronary Artery Disease (Cad) Patients With Clopidogrel Hypersensitivity After Percutaneous Coronary Intervention (Pci) Cegec, I.
 2016
 38 10S p. e28-
1 p.
 article
59 Pharmacoeconomics: How It Can Be Applied To Support Decisions In Health Care? Vitezic, D.
 2016
 38 10S p. e13-
1 p.
 article
60 Pregnancy Exposure to Drugs: Role of Clinical Pharmacologist Radacic Aumiler, M.
 2016
 38 10S p. e21-
1 p.
 article
61 Rapid Health Technology Assessment Of New Medicines: Lessons From 15 Years Experience In Scotland Paterson, K.R.
 2016
 38 10S p. e13-
1 p.
 article
62 Regulation Of Orphan Medicinal Products In Europe: History Trends And Challenges Sepodes, B.
 2016
 38 10S p. e7-e8
nvt p.
 article
63 Safe Introduction of New Medicines Into Clinical Practice Maxwell, S.
 2016
 38 10S p. e8-
1 p.
 article
64 Sodium Selenate Restores Potassium Currents of Diabetic Cardiomyopathy: Rat Model Study Yanardag, S.B.
 2016
 38 10S p. e30-e31
nvt p.
 article
65 Standardization of In Vivo Drug Assessment Protocol For Testing Anti-Diabetic Plants: Effect And Possible Mechanism of Action of Fabaceae Beans Senbel, A.
 2016
 38 10S p. e32-
1 p.
 article
66 Table of Contents 2016
 38 10S p. A3-
1 p.
 article
67 Testing for Hypersensitivity to Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) At the University Hospital Zagreb Kraljickovic, I.
 2016
 38 10S p. e25-
1 p.
 article
68 The Analysis Of Lipid Modifying Agents Usage In Croatia During The Fifteen-Year Period Kucan, M.
 2016
 38 10S p. e10-
1 p.
 article
69 The Effects of SENS-111, A New H4R Antagonist, On Vertigo Induced by Caloric Test in Healthy Volunteers (HV) is Related to Plasma Concentrations Attali, P.
 2016
 38 10S p. e4-
1 p.
 article
70 The Modification of Anti-Inflammatory Properties of the Combined use of Nsaids and Glucosamine in Topical Dosage Form for Degenerative and Inflammatory Joint Diseases Treatment Davishnia, N.V.
 2016
 38 10S p. e24-
1 p.
 article
71 The Need For Medical Information In Relation To Diabetes Self-Management Among Emirati Women In United Arab Emirates Abuelmagd, W.
 2016
 38 10S p. e29-
1 p.
 article
72 The Role Of Cyp2d6, Cyp3a4/5, And Abcb1 Polymorphisms In Patients Using Long-Acting Injectable Risperidone Ganoci, L.
 2016
 38 10S p. e10-e11
nvt p.
 article
73 The Role Of Pharmacogenetics In Individualized Treatment Choices Bozina, N.
 2016
 38 10S p. e7-
1 p.
 article
74 The Role of Pharmacogenetic Testing in the Evaluation of Drug-Induced Liver Injury Stanić Benić, M.
 2016
 38 10S p. e24-e25
nvt p.
 article
75 The Role of the National Competent Authority (NCA) In the Assessment of Medicinal Products in the National Procedure Tomic, S.
 2016
 38 10S p. e2-
1 p.
 article
76 The Use of Drugs for The Elderly With Community-Acquired Pneumonia Tilekeeva, U
 2016
 38 10S p. e27-e28
nvt p.
 article
77 Trend of Biosimilars Prescribing In A Croatian Teaching Hospital Stanic Benic, M.
 2016
 38 10S p. e28-
1 p.
 article
78 Use of Health Technology Assessment Agencies' Reports As Evidence For Making Decisions On Drug Reimbursement In Decentralized Decision-Making Environment Mahmic-Kaknjo, M.
 2016
 38 10S p. e30-
1 p.
 article
79 Vascular Consequences Of Interruption Of Tnf-Inhibitor Therapy In Patients With Rheumatoid Arthritis Rongen, G.A.
 2016
 38 10S p. e8-
1 p.
 article
80 Why Abc/Ved Analysis In Oncology? The Experience Of A Major Russian Oncology Center Pavlysh, A.V.
 2016
 38 10S p. e18-
1 p.
 article
81 Why Reporting The Iodinated Contrast Media Used During Radiological Procedures Should Be Standard Practice: A Case Report Juricic Nahal, D.
 2016
 38 10S p. e31-
1 p.
 article
                             81 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands